

Correct Dx Key to Primary Ovarian Insufficiency

BY DAMIAN McNAMARA

SAN ANTONIO — Make the diagnosis, inform the parents first, and consider full hormone replacement therapy when an adolescent girl presents with irregular menses suggestive of primary ovarian insufficiency, Dr. Lawrence M. Nelson advised.

“The No. 1 thing I am going to ask you to do regarding primary ovarian insufficiency is to make a diagnosis,” he said at the annual meeting of the North American Society for Pediatric and Adolescent Gynecology.

Take amenorrhea seriously, Dr. Nelson said. Although the commonly held view is “that anything goes with the menstrual

the fertility effects early on may do more harm—that is one of my concerns.”

Offer the adolescent advice on how to minimize or avoid stigma and to develop positive self-esteem and body image. Physician counseling can make a difference in self-esteem, anxiety, and depression associated with POI, based on a study by Dr. Nelson and his colleagues (*Fertil. Steril.* 2009 [doi:10.1016/j.fertnstert.2008.12.122]).

After diagnosis and counseling, treatment considerations are next. “Unlike postmenopausal women, it’s full hormone replacement for these [girls],” he said.

There are multiple treatments and regimens available, and he recommended a review article that outlines how to induce puberty for adolescent patients (*Ann. N.Y. Acad. Sci.* 2008;1135:204-11). This publication discusses the benefits

and risks of hormone replacement therapy—including special concerns about bone health and eating disorders—in this population.

Although common, follicular depletion associated with POI cannot be proven definitively. “It is now clear the ovarian failure is not permanent in all women,” Dr. Nelson said. Rarely, “some women get pregnant with this diagnosis.” ■



‘Placing too much emphasis on the fertility effects early on may do more harm—that is one of my concerns.’

DR. NELSON

cycle when you are a teenager,” irregularities can signal a serious condition. “When someone comes in with hypothyroidism, they get [thyroid-stimulating hormone] measured. When the menstrual cycle is abnormal, people will just say it’s stress,” said Dr. Nelson, head of the integrative reproductive medicine unit at the National Institute of Child Health and Human Development.

Any adolescent girl who has not had menses for 90 days or longer should be evaluated further. Any girl without signs of pubertal development or onset of menses by age 13 also may have primary ovarian insufficiency (POI).

Target your evaluation based on history and physical examination and check hormone levels, including follicle-stimulating hormone, Dr. Nelson said.

A disturbance in the menstrual cycle was the leading initial symptom reported by 48 women surveyed after diagnosis with spontaneous premature ovarian failure (*Obstet. Gynecol.* 2002;99[pt. 1]:720-5). More than half of the respondents consulted three or more clinicians before a laboratory diagnosis was made. The median delay in diagnosis was 2 years, and for 25% it took longer than 5 years.

Once you make the diagnosis, use a family systems approach to counseling, Dr. Nelson said. “It is important to inform the parents first and then the patient. It is not a good idea, in our experience, to explain it to the parents and child at the same time.” This approach gives parents an opportunity to absorb the news and, in many cases, to grieve their loss of future grandchildren. Also, provide parents with tools that facilitate an ongoing conversation with the child.

Inform both parents and the patient with sensitivity, Dr. Nelson said. Use accurate terminology, provide information, and make appropriate psychosocial referrals. “Placing too much emphasis on

IN THE TREATMENT OF ATROPHIC VAGINITIS, A CHRONIC CONDITION

VAGIFEM®

a therapy she can stay with

**It's clean.¹
It's simple.²
It's effective.²
It's well tolerated.²**

For information or samples visit NovoMedLink.com/HT or call 1-866-668-6336.

Model is used for illustrative purposes only.

Vagifem® is indicated for the treatment of atrophic vaginitis.

Important Safety Information

ESTROGENS HAVE BEEN REPORTED TO INCREASE THE RISK OF ENDOMETRIAL CARCINOMA.

Three independent, case-controlled studies have reported an increased risk of endometrial cancer in postmenopausal women exposed to exogenous estrogens for more than one year. This risk was independent of the other known risk factors for endometrial cancer. These studies are further supported by the finding that incident rates of endometrial cancer have increased sharply since 1969 in eight different areas of the United States with population-based cancer-reporting systems, an increase which may be related to the rapidly expanding use of estrogens during the last decade.

The three case-controlled studies reported that the risk of endometrial cancer in estrogen users was about 4.5 to 13.9 times greater than in nonusers. The risk appears to depend on both duration of treatment and on estrogen dose. In view of these findings, when estrogens are used for the treatment of menopausal symptoms, the lowest dose that will control symptoms should be utilized and medication should be discontinued as soon as possible. When prolonged treatment is medically indicated, the patient should be re-assessed, on at least a semiannual basis, to determine the need for continued therapy.

Close clinical surveillance of all women taking estrogens is important. In all cases of undiagnosed persistent or reoccurring abnormal vaginal bleeding, adequate diagnostic measures should be undertaken to rule out malignancy. There is no evidence at present that “natural” estrogens are more or less hazardous than “synthetic” estrogens at equi-estrogenic doses.

Other warnings include: induction of malignant neoplasms, gallbladder disease, effects similar to those caused by estrogen-progestogen oral contraceptives (such as thromboembolic disease, hepatic adenoma, elevated blood pressure, worsening of glucose tolerance), hypercalcemia, and rarely, trauma induced by the Vagifem® applicator.

In a placebo-controlled clinical trial, the most commonly reported adverse events included: headache (9%), abdominal pain (7%), upper respiratory tract infection (5%), genital moniliasis (5%), and back pain (7%).

The use of Vagifem® is contraindicated in women who exhibit one or more of the following: known or suspected breast carcinoma, known or suspected estrogen-dependent neoplasia (e.g., endometrial carcinoma), abnormal genital bleeding of unknown etiology, known or suspected pregnancy, porphyria, hypersensitivity to any Vagifem® constituents, active thrombophlebitis or thromboembolic disorders, or a past history of thrombophlebitis, thrombosis, or thromboembolic disorders associated with previous estrogen use (except when used in treatment of breast malignancy).

Please see brief summary of Prescribing Information on adjacent page.



Vagifem® is a registered trademark of Novo Nordisk FemCare AG.
References: 1. Data on file. Development report 448-2794 Vagifem. Novo Nordisk Inc, Princeton, NJ.
2. Data on file. Study report/VAG/PD/5/CAN. Novo Nordisk Inc, Princeton, NJ.
© 2009 Novo Nordisk Inc. Printed in the U.S.A. 137009 January 2009

